Diagnosed at 46, Quebec woman with stage 4 breast cancer calls for earlier screening - CityNews Montreal

Country star diagnosed with rare blood cancer after health scare: ‘One day at a time’Digital Content ManagerNASHVILLE, Tenn. —Charles Kelley, the singer and songwriter best known as a founding member of the country trio Lady A, revealed he’s been diagnosed with a rare blood cancer. The 44-year-old Grammy winner shared the news on Instagram this week, saying that doctors have diagnosed him with multiple myeloma – a rare blood cancer in which abnormal plasma cells grow in the bone marrow. Kelley said it started with him going to the doctor to address a few “random” rib fractures, which prompted several blood tests from doctors. Related video above | Lady A’s Charles Kelley talks touring with his son"And one of the blood tests we did, they found a blood cancer in there called multiple myeloma and it's rare," he said. Despite his diagnosis, Kelley said he’s hopeful. "I'm young. I feel healthy. The treatments, I will have to say, have just come so far, even in the past five years that, even life expectancy just far exceeds what it used to be," Kelley said. His diagnosis does not mean an end to the music. "I can still work. I think physically I will feel like myself,” he said.

Cosmos StudySeptember 29, 2026Dual-Team StudyTeam A:Kersten Bartelt, RNGrant KeaneTeam B:Tony Dunnigan, MDNicholas VolkerKey Findings For nearly every mental health condition we studied, rates of diagnoses were higher among patients with a diagnosed gambling disorder than among those without.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.